Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharma Companies Join HIV Consortium
by Ann M. Thayer
July 30, 2012
| A version of this story appeared in
Volume 90, Issue 31
A public-private partnership, called the Collaboration for HIV/AIDS Immunological Therapy, has been set up to combat HIV. CHAIT is being supported by the Swiss Vaccine Research Institute, France’s Vaccine Research Institute, Boehringer Ingelheim, FIT Biotech, GlaxoSmithKline Vaccines, Sanofi Pasteur, and ViiV Healthcare. The partners want to develop immunological approaches, including vaccines and immunomodulators, to achieve a “functional cure,” or remission state with long-term control of the virus in the absence of antiretroviral therapy. They also hope to work with regulators to define new criteria for therapeutic response.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter